Reverse Recapitalization (Details) $ / shares in Units, $ in Thousands			12 Months Ended
	May 24, 2021 USD ($) $ / shares shares	May 23, 2021	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) shares
Business Acquisition [Line Items]
Earnout shares for common stockholders			22,209,280
Earnout cash for common stockholders | $			$ 88,800
Aggregate purchase price | $				$ 9,624
Substitute Warrants
Business Acquisition [Line Items]
Closing Consideration (in shares)	935,608
Substitute Options
Business Acquisition [Line Items]
Closing Consideration (in shares)	1,920,492
Merger agreement
Business Acquisition [Line Items]
Closing Consideration (in shares)	25,000,000
Contingent Consideration | $	$ 100,000
Exchange Ratio	3.16	4.96
Stock Issued During Period, Shares, New Issues				3,729,730
Merger agreement | Subscription agreements
Business Acquisition [Line Items]
Issue price (in dollars per share) | $ / shares			$ 10.00
Stock Issued During Period, Shares, New Issues			1,000,000
Aggregate purchase price | $			$ 10,000
Merger agreement | Stockholders of NeuroRx
Business Acquisition [Line Items]
Exchange Ratio	3.16	4.96	3.16
Consideration (in shares)	50,000,000
Issue price (in dollars per share) | $ / shares	$ 0.001